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 Samenvatting 
Achtergrond 
Screeningsresultaten uit immunoassays, bioassays en microbiologische testplaten die niet bevestigd 
kunnen worden in de daaropvolgende chemische analyse werden tot voor kort als “vals-verdachte” 
screeningsresultaten terzijde gelegd. Sinds de ontdekking van illegale synthetische varianten, zoals de 
beta-agonist Clenbuterol-R en het anabole steroid THG in de sportdoping, bestaat de behoefte om in 
het kader van de opsporing van verboden middelen meer te doen aan de identificatie van bioactieve, 
mogelijk onbekende, (il)legale dierbehandelingsmiddelen. In surveys en quickscans is het wenselijk 
om in relatief korte tijd een zo breed mogelijk beeld te krijgen van residuen van 
dierbehandelingsmiddelen in bepaalde matrices. De introductie van UPLC/TOFMS en OrbitrapMS 
technologie biedt de mogelijkheid om grote groepen dierbehandelingsmiddelen in korte tijd chemisch 
te screenen. 
 
Doel 
Ontwikkeling en toepassing van massaspectrometrische identificatiemethoden voor nieuwe en 
bekende (il)legaal toegepaste dierbehandelingsmiddelen. 
 
Resultaten in 2008 
De effectgestuurde onderzoeksmethode bestaat uit een combinatie van een bioassay met een 
UPLC/TOFMS instrumentele analyse. Het onderzoek is uitgevoerd aan 14 zogenaamde “cold-cases”, 
oude monsters voedersupplementen en –preparaten, waarin destijds geen relevante stoffen konden 
worden aangetoond ondanks het feit dat er volgens de informatie van de AID sprake was van 
bioactieve werkzaamheid, en aan acht monsters kruidenpreparaten en sportsupplementen die mogelijk 
stimulerende bioactieve stoffen bevatten en in de loop van 2008 zijn verzameld. De monsters zijn in 
eerste instantie onderzocht met behulp van een experimentele bioassay die bestaat uit gemodificeerde 
gistcellen die na blootstelling aan androgene stoffen fluorescentie vertonen. Er is tevens een aantal 
specifieke (bio)activeringen toegepast om naast de directe androgenen ook pro-androgenen, 
androgeen-esters en geconjugeerde androgenen en pro-androgenen te kunnen bepalen. Uit de 
resultaten blijkt dat in geen van de “cold cases” androgene activiteit wordt gedetecteerd, ook niet na 
specifieke activering. Hieruit wordt geconcludeerd dat deze monsters geen androgenen, pro-androgen, 
androgeen-esters of geconjugeerde androgenen of pro-androgenen bevatten. Twee van de vier 
kruidenpreparaten bleken positief te zijn in de bioassay, terwijl drie van de vier sport supplementen 
"indicatief" of toxisch reageerden in de bioassay. Een indicatieve respons wijst op de aanwezigheid 
van androgeen-achtige stoffen en kan aanleiding zijn tot verder onderzoek. De positieve 
kruidenmonsters zijn gefractioneerd met LC, de fracties opnieuw op bioactiviteit getest en de positieve 
fracties geanalyseerd met UPLC/TOFMS. In de positieve fractie van één monster werden 
testosteronphenylacetaat (of het structurele isomere nortestosteronphenylpropionaat) en 
testosteronhexahydrobenzoaat aangetroffen. In het tweede monster werd een methyltestosteron 
isomeer geïdentificeerd. Door een onafhankelijke analyse met chemische standaarden konden de 
identiteiten worden bevestigd als nortestosteronphenylpropionaat en 17α-methyltestosteron die in de 
monsters aanwezig waren in geschatte concentraties van respectievelijk 0,2 en 4 mg/kg product.  
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 In het kader van dit project, de identificatie van onbekende stoffen, is voor de UPLC/TOFMS analyse 
een accurate massa database ontwikkeld op basis van de PubChem database die op het internet kan 
worden gevonden. Dit heeft in eerste instantie geleid tot een off-line versie in Windows Access format 
en voorzien van een gebruikersinterface waarin de zoekcriteria zoals accurate massa en massa window 
kunnen worden opgegeven. Daarnaast is de accurate massa database ook gekoppeld met de TOFMS 
software om on-line onbekende componenten te kunnen identificeren in de sportsupplementen die 
indicatief en toxisch reageerden in de bioassay. Door de UPLC/TOFMS data files vooraf te bewerken 
met MetAlign (in-huis ontwikkelde software voor het opschonen van MS data) en deze files verder te 
processen was het mogelijk onbekende componenten in de chromatogrammen van de extracten van de 
sportsupplementen te identificeren. Dit leidde in drie sportsupplementen tot de identificatie van de 
androgenen methylboldenon en testosteron, en de androgeen esters methyltestosteronpropionaat (of 
het isomere testosteronisobutyraat), testosteronbuciclaat en methyleentestosteronacetaat. Daarnaast 
werden in deze monsters een aantal norcodeine- of morphine-achtige componenten geïdentificeerd. 
 
Conclusie 
In de “cold cases” zijn geen stoffen met androgene werking aangetoond. Bioassay gestuurde 
fractionering gecombineerd met UPLC/TOFMS analyse blijkt in staat stoffen met androgene werking 
te kunnen detecteren, isoleren en identificeren. In twee kruidenmengsels die als sport supplementen 
worden toegepast zijn zo androgenen en respectievelijk androgeen esters gedetecteerd en na analyse 
met UPLC/TOFMS geïdentificeerd. Daarnaast blijkt de combinatie van UPLC/TOFMS analyse met 
een accurate massa database goed in staat onbekende componenten te identificeren. Met deze methode 
werden in dit onderzoek meerdere androgenen en androgeen esters in drie sportsupplementen 
geïdentificeerd. Het doel van dit onderzoek is hiermee gehaald.     
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 Summary 
Background 
Nowadays a large number of compounds are determined in environmental and food samples. 
Biological tests are used to screen samples for large groups of compounds having a particular effect, 
but it is often difficult to identify a specific compound when a positive effect is observed. The 
identification of an unknown compound is a challenge for analytical chemistry in environmental 
analysis, food analysis, as well as in clinical and forensic toxicology. This study reports on the 
development of a procedure for the identification of unknown residues in samples suspected of 
containing illegal substances and samples showing bioactivity in bioassay- or microbiological 
screening assays. For testing purposes several samples were selected; a number of so-called “cold 
cases”, historical samples that were suspected of containing illegal growth promoting substances, 
herbal mixtures and sport supplements. 
 
Aims 
The development of an identification procedure for unknown biological active compounds using liquid 
chromatography in combination with time-of-flight mass spectrometry.  
 
Results 
In this study bioassay directed fractionation combined with UPLC/TOFMS identification was tested as 
a method to detect and identify unknown androgens. Test samples comprised of a series of “cold 
cases”, feed supplements suspected to contain growth promoting substances already analyzed in the 
past, however, without detecting any such compounds. A second set of samples consisted of herbal 
mixtures and sport supplements suspected to contain compounds with androgenic activity. The results 
of the androgen bioassay tests on “cold cases” showed that none of the “cold-case” samples contained 
compounds with androgenic activity. Not only the direct androgen bioassay showed no response, but 
also the tests for pro-androgens, androgen esters and conjugated androgens and pro-androgens were 
negative indicating that no compounds are present that can be metabolically converted into androgens. 
Two of the four herbal mixtures tested positive, one for the presence of an androgen, another for an 
androgen ester. Bioassay guided fractionation of the positive herbal mixtures resulted in the fractions 
of the sample chromatogram where the androgenic compounds elute. Further analysis of these 
fractions with UPLC/TOFMS resulted in the tentative identification of a methyltestosterone in one of 
the samples and testosterone phenylacetate (or the isomeric nortestosterone phenylpropionate) and 
testosterone hexahydrobenzoate in another. Using a confirmation method the methyltestosterone 
isomer in the herbal mixture was standard confirmed as 17α-methyltestosterone present in a 
concentration of approximately 4 mg/kg product. The identity of the androgen ester was standard 
confirmed as nortestosteron phenylpropionate with a concentration of 0.2 mg/kg product in the herbal 
mixture. An accurate mass database containing approximately 40,000 compounds was developed 
based on the PubChem database on the internet. At first this database was developed into an off-line 
custom database in Windows Access format with a user interface for entering search parameters and a 
link to the original PubChem database. The database was also coupled to the TOFMS software 
allowing reversed searching and automatic identification of chromatographic peaks without primary 
reference standards. The combination of UPLC/TOFMS with data processing and accurate mass 
database searching was used to analyze the sport supplements since these were negative, inconclusive 
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 or reacted toxic in bioassay tests. Without the use of primary reference standards the analysis resulted 
in the identification of several androgens, including methylboldenone, testosterone and the androgen 
esters methyltestosterone propionate or testosterone isobutyrate, testosterone buciclate and 
methylenetestosterone acetate in the sport supplements. In addition, a number of norcodeine- or 
morphine-like compounds were found in these samples. 
 
Conclusion 
The “cold-case” samples do not contain any androgens, pro-androgens, androgen esters or conjugated 
androgens. The study showed that bioassay guided fractionation in combination with UPLC/TOFMS 
analysis is a successful procedure to detect and identify unknown androgens in herbal mixtures and 
sport supplements. The use of large databases without primary standards and coupled with the 
instrument software enables the automatic identification of peaks in the chromatogram and looks very 
promising for unknown identification. The aims of the study have been met.  
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 1 Introduction 
Nowadays a large number of compounds are determined in environmental and food samples. In almost 
all cases this concerns substances that are already known and the general concern is to confirm their 
presence and to determine the concentrations of these substances. However, many more substances for 
which no specific tests are performed may be present in the sample. Biological tests can be used to 
screen samples for large groups of compounds having a particular effect, but it is often difficult to 
identify a specific compound when a positive effect is observed. Similar problems are encountered in 
toxicological analysis, for instance in cases of acute poisoning. The identification of an unknown 
compound is a challenge for analytical chemistry in environmental analysis, food analysis, as well as 
in clinical and forensic toxicology. The screening of unknown compounds is also called “General 
Unknown Screening” (GUS) or sometimes “Systematic Toxicological Analysis” (STA) (De Zeeuw 
1997; Sturm 2005). The purpose of such methods is to identify (xenobiotic) substances in 
environmental, food and biological matrices. Following the usual course of STA, samples will initially 
be analyzed by immuno- or bioassays (Ferrara et al. 1994; Nielen et al. 2003 and 2004; Hino et al. 
2003). These preliminary biological screening procedures mainly concern rapid-response analytical 
tools providing a binary “yes/no” response, which indicates whether the target analytes are present 
above a preset concentration threshold or not. Samples providing a “yes“ response to one or more 
compound classes or target substances are than analyzed with a confirmation method.  
 
Analysis of veterinary drugs, hormones, pesticides and their metabolites in food and biological 
samples is an important routine task for food safety, doping control and clinical and forensic 
toxicology laboratories. Monitoring of these compounds is a particularly demanding task for both 
analytical and interpretive reasons, because of the extremely wide range of substances, in terms of 
molecular weight, polarity, pKa, and chemical/thermal stability. As a consequence, recently several 
examples of broad screening methods for known compounds in environmental, food, feedstuff, 
toxicological and biological samples have appeared (Lacorte et al. 2006; Marques et al. 2006; Portolés 
et al. 2007; Kolmonen et al. 2007, Kaufmann et al. 2007; Mol et al. 2008; Kaufmann et al. 2008; 
Stolker et al. 2008; Peters et al. 2009). Even more than these methods, GUS and STA procedures 
require the primary extraction to be generic and non-discriminative against relevant compounds. 
Purification methods like SPE can be used to remove non-relevant substances and matrix 
interferences, but should be used with caution since they will compromise the generic nature of the 
sample preparation. An exception can be made if the unknown compound belongs to a certain class of 
compounds, for instance estrogens, β2-agonists or antibiotics, and the bioassay is able to differentiate 
between these compound classes. This would allow a compound-class directed clean-up procedure to 
remove non-relevant compounds. The next step in GUS is a separation of the analytes, often using 
chromatography.  
 
While many methods have been used in the last few years, it is safe to say that liquid chromatography 
(LC) is the most generic of these, and since the introduction of high resolution LC (HRLC) also one of 
the most selective. HRLC, ultra performance LC (UPLC) and ultra high performance LC (UHPLC) 
are all synonyms for LC separations on sub-2-μm particulate packing materials which provides 
significant advantages concerning selectivity, sensitivity and speed. Gas chromatography (GC) has 
been used but is limited to apolar, volatile and thermally stable compounds (Maurer 2004). Finally, the 
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 detection should be generic and sensitive, allowing the identification of compounds using databases or 
reference substances. Coupling of mass spectrometry (MS) to LC seems to be the possibility to 
increase the range of compounds amenable to MS (Marquet 2002). Especially full mass scan MS 
techniques like time-of-flight MS (TOFMS) or OrbitrapMS provide high specificity due to both, high 
mass accuracy and high mass resolution and allow the reconstruction of highly selective accurate mass 
chromatograms of target residues in complex matrices. The advantage of TOFMS and OrbitrapMS 
analyzers is their ability to analyze a sample for a theoretically unlimited number of compounds and 
therefore, the combination of these analyzers with LC is capable of screening for several hundreds of 
compounds with high sensitivity within one run. Furthermore, data can be acquired and reprocessed 
without any a priori knowledge about the presence of certain compounds; that is, no analyte-specific 
information is required before injecting a sample and the presence of newly identified compounds can 
be confirmed in previously analyzed samples simply by reprocessing the data. The advantage of these 
analyzers can be further improved by combining it with HRLC. In the screening of veterinary drugs 
HRLC-TOFMS has been shown to provide significant advantages concerning selectivity, sensitivity 
and speed (Kaufmann et al. 2007 and 2008; Mol et al. 2008; Stolker et al. 2008; Peters et al. 2009). 
For HRLC-OrbitrapMS these advantages are even higher, because of the higher selectivity and 
sensitivity of the OrbitrapMS when compared to TOFMS (Van der Heeft et al. 2009). 
 
The use of HRLC/TOFMS generates an enormous amount of data potentially allowing the 
identification of unknown compounds. However, depending on the matrix, the enormous amount of 
data can also cause problems in identification, because screening may be hampered by matrix 
interferences and manual searching of TOFMS data for unknown compounds is difficult. The large 
number of peaks in a chromatogram may result in a “forest of peaks” making it difficult to distinguish 
between true compounds of interest or “active” compounds, and compounds resulting from the matrix 
or endogenously compounds from biological matrices. One way to pinpoint the bioactive unknown 
compounds is generally known as bioassay directed fractionation. The sample extract is then 
fractionated with the help of LC and the eluent split in a dual collection system with 96-well micro-
titre plates. Collection is usually carried out as a function of time and a fraction volume of up to 300 
µL is used depending on the type of bioassay (Dittmann et al. 2004; Vuorela et al. 2004; Waridel et al. 
2004; Queiroz et al. 2005). The LC-MS data from the original sample extract or the separate fractions 
can be matched and correlated with the bioactivity profile from the separate fractions to identify peaks 
of bioactive compounds in the chromatogram. Finally, this information can be used to search 
compound databases for the tentative identification of the bioactive unknown compounds. While this 
procedure is primarily used in the identification of natural products (Hamburger 2003; Wennberg 
2006; Han et al. 2009) it has also been used in the analysis of steroids in surface water (Beck et al. 
2006) and urine (Nielen et al. 2004 and 2006), and veterinary drug residues in food and feed 
(Marchesini et al. 2007). This methodology is illustrated in Figure 1. 
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Figure 1. Schematic presentation of bioassay guided fractionation and identification of unknown bioactive 
compounds in bioactive fractions using UPLC-TOFMS. 
While LC/MS is a more generic detection technique than GC/MS it also has a disadvantage. Different 
from GC/MS, LC/MS techniques generally do not produce interpretable full mass spectra, firstly since 
the soft ionization techniques used show little or no fragmentation, secondly because techniques like 
in-source collision-induced dissociation (CID) show spectra with poor reproducibility, especially 
when acquired with instruments from different manufacturers. As a consequence, searchable databases 
as the well known National Institute for Standards and Testing (NIST) mass spectral library for 
GC/MS are virtually absent for LC/MS (NIST 2008). It is the unavailability of such mass databases 
that doesn’t allow a rapid screening of samples with LC/MS. In contrast, accurate mass measurements 
like those performed by high resolution TOFMS are specific and universal for every compound 
regardless of the instrumentation used, potentially enabling the use of mass databases. Thurman used 
this approach, a combination of TOF data and the Merck Index to identify pesticides in food, including 
degradation products, without the initial use of primary standards (Thurman et al. 2005; Ferrer et al. 
2006). Another interesting approach was used by Laks who determined street drugs without primary 
reference materials. Identification was performed by LC/TOFMS essentially based on accurate mass 
determination using a target database of 735 exact monoisotopic masses (Laks et al. 2004). To prepare 
the database theoretical monoisotopic exact masses of compounds were calculated from their 
molecular formula. Peaks in a chromatogram were identified using a mass window criterion of ±20 
ppm for compounds of >200 Da and ±30 ppm for compounds <200 Da. In addition a minimum area 
count was used and a retention window of ±0.2 min if a retention time was available. A similar 
procedure was used for the screening of drug residues but included isotopic pattern matching as an 
orthogonal criterion for compound identification (Ojanperä et al. 2006). Of course, without primary 
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 reference standards identifications have only a tentative character and the identity should be confirmed 
using the actual standard compounds in a suitable confirmation method. 
 
This study reports on the development of a procedure for the identification of unknown residues in 
samples suspected of containing illegal substances and samples showing bioactivity in immunoassays, 
bioassays or other microbiological screening assays. For testing purposes a number of so-called “cold 
cases” were selected, historical samples that were suspected of containing illegal substances (in 
particular hormones), but whose presence was never confirmed with bioassays or chemical analysis. In 
addition, a number of herbal preparations and sport supplements, also called ergogenic aids, were 
tested. The development of the identification procedure contains the application of an existing 
bioassay directed identification procedure in combination with advanced HRLC/TOFMS techniques 
and the development of a database for compound identification in LC/TOFMS analysis. 
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 2 Methods 
2.1 Chemicals and reagents 
All solvents were of HPLC-grade or higher. Acetonitrile, methanol acetone, isooctane and water used 
for LC/MS measurements were purchased from Biosolve (Valkenswaard, The Netherlands). Water 
used for sample preparations was purified using a Millipore Milli-Q system (Bedford, MA, USA). 
Sodium acetate, sodium (bi)carbonate and leucine-enkephalin were purchased from Sigma 
(Zwijndrecht, The Netherlands). Ethyl acetate, formic acid, acetic acid, sodium acetate, sodium 
carbonate, sodium chloride, di-sodium hydrogen phosphate dihydrate, sodium dihydrogen phosphate 
monohydrate, ammonium sulphate, magnesium chloride, potassium chloride, 
tris(hydroxymethyl)aminomethane (Tris), dimethylsulfoxide (DMSO), hydrochloric acid and acetic 
acid were purchased from Merck (Darmstadt, Germany). Glucose-6-phosphate, NADH disodium salt, 
NADP disodium salt and NADPH tetrasodium salt were from Roche Diagnostics (Almere, the 
Netherlands). Dextrose and yeast nitrogen base without amino acids and without ammonium sulphate 
were from Difco (Detroit, MI, USA). L-Leucine, bovine serum albumin (BSA), hydroxysteroid 
dehydrogenase originating from Pseudomonas, testosterone and NAD sodium salt were purchased 
from Sigma (St. Louis, MO, USA).  
2.2 Samples 
Two different types of samples were involved in this study. The first group consisted of historical 
samples received from the AID because they suspected these samples to contain illegal substances. All 
samples were received in the period from 2005 to 2008. At the time of their receipt the samples were 
generally analyzed using NMR, a number of targeted chemical analyses, and sometimes a 
chloramphenicol immunoassay and an estrogen bioassay. The samples that were used in this study and 
the results of their analysis at that time are as follows:  
 
RIKILT-code Sample description Results of prior analysis 
200141597 feed negative 
200141598 feed negative 
200144635 feed bigbag positive for estrogens 
200144690 supplement for hypophysis activity negative 
200145516 cod-liver oil negative 
200145518 herbal mixture negative 
200146583 herbal mixture positive for dexamethasone 
200146585 herbal mixture positive for dexamethasone 
200146589 herbal mixture positive for dexamethasone 
200148736 all mash negative 
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 RIKILT-code Sample description Results of prior analysis 
200166957 feed negative 
200207042 herbal mixture positive for chloramphenicol 
200207177 digestamin piglet positive for estrogens 
200207178 digestamin fattening negative 
 
 
In addition, a number of sport supplements were used in this study. These samples were received from 
sport schools or intermediates. The supplements are the following: 
 
Name Sample description Intended use 
Herb A1 brownish herbs in brown capsule 
chinese herbs for improved 
performance in sports 
Herb A2 brownish herbs in brown capsule 
chinese herbs for improved 
performance in sports 
Herb A3 reddish herbs in orange capsule 
indonesian herbs for improved 
performance in sports 
Herb A4 reddish herbs in orange capsule  
indonesian herbs for improved 
performance in sports 
Suppl. S1 white powder in capsule sports supplement 
Suppl. S2 white powder in capsule sports supplement 
Suppl. S3 white powder in capsule sports supplement 
Suppl. S4 white powder in capsule sports supplement 
2.3 Sample analyses 
2.3.1 Sample preparation for androgen bioassay 
The sample preparation method is comparable to some of the recent published multi-methods. A 
sample of 3 gram is mixed with 6 ml methanol and 6 ml sodium acetate buffer (0.25M; pH 4.8) and 
shaken by hand. Next, it is placed 10 min in an ultrasonic bath followed by 15 min in a head-over-
head apparatus. Finally, the mixture is centrifuged for 15 min at 3500 g and 6 ml of the supernatant is 
collected in a glass tube. To this 150 µl acetic acid (4.0 M) is added and the pH checked to be about 
4.8. For the first SPE purification a Varian C18 cartridge (1000 mg, 6ml) is conditioned with 4 ml 
methanol followed by 3 ml of a 1:1 mixture of methanol and sodium acetate buffer (0.25M; pH 4.8) 
before applying the 6 ml extract to the cartridge. The cartridge is washed in succession with 3 ml of a 
1:1 mixture of methanol and sodium acetate buffer (0.25M; pH 4.8), 6 ml milli-Q water, 3 ml of a 
sodium carbonate solution (0.25M), 3 times 6 ml milli-Q water and 2 times 4 ml of a 1:1 mixture of 
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 methanol and milli-Q water. The cartridge is dried for 10 min by applying vacuum and eluted with 2 
times 4 ml acetonitrile. Again, the eluates are collected in a glass tube to avoid contamination from 
plastic materials. For the second SPE purification an Isolute NH2 cartridge is activated with 4 ml of 
acetonitrile. The 8 ml eluate of the first SPE is brought on top of the cartridge and the eluate is 
collected in a glass tube. Finally, the eluate is evaporated to dryness under a stream of nitrogen gas in 
a TurboVap apparatus at 40°C and the residue reconstituted in 3 ml of acetonitrile.  
2.3.2 Sample pre-treatment for glycosides (enzymatic digestion) 
In order to remove glycoside groups from androgens an enzymatic digestion of the sample is included 
as a pre-treatment. Typically, a sample of 100 mg is mixed with 4 ml sodium acetate buffer (0.25M; 
pH 4.8) and shaken by hand. Next, 110 µl glucuronidase reagent is added for an enzymatic 
deconjugation for 3 h at 52°C. After cooling to room temperature 4 ml methanol is added, the mixture 
vortexed and shaken for 10 min in a head-over-head apparatus. The mixture is centrifuged for 15 min 
at 3500 g and 4 ml of the supernatant is collected in a glass tube. The pH is checked and if necessary 
corrected to 4.8 by the addition of acetic acid (4.0 M). An SPE purification is applied using an Oasis 
HLB cartridge (60 mg, 3ml) conditioned with 2 ml methanol followed by 2 ml of milli-Q water before 
applying the 4 ml extract to the cartridge. The cartridge is washed in succession with 2 ml of milli-Q 
water, 2 ml of a 1:1 mixture of methanol and milli-Q water. The cartridge is dried for 10 min by 
applying vacuum and eluted with 4 ml methanol.  
2.3.3 Sample preparation for pro-hormones (enzymatic activation) 
Pro-hormones in the sample can be detected only after activation and therefore an enzymatic 
activation using an S9 mixture is applied as a pre-treatment. Typically, 100 µl of the final SPE eluent 
from samples (see “Sample preparation for androgen bioassay”) was evaporated to dryness in a glass 
tube and the residue incubated with 500 µl sodium phosphate buffer (0.2M; pH 7.4), 50 µl glucose-6-
phosphate (0.2M), 20 µl potassium chloride solution (1.65M), 20 µl magnesium chloride solution 
(0.4M), 100 µl bovine S9 mixture (20 mg/ml in a Tris-HCl buffer of 50 mM, pH 7.4, 1.15% KCl) and 
40 µl NAD or NADPH (0.1M). The final volume was made up to 1.0 ml using milli-Q water, the tube 
closed and incubated at 37°C in a water bath for 6 h. Blanks without bovine liver S9 and blanks 
without cofactor were included to check for non-enzymatic reactions during the incubation period. 
Reactions were terminated at t=0 and t=6 h by the addition of 1 ml acetonitrile and the mixture 
centrifuged for 15 min at 3000 g. The supernatant was collected, the residue extracted once more with 
2 ml acetonitrile and centrifuged for 10 min at 3000 g. The combined supernatants were evaporated to 
appr. 0.5 ml and diluted with 3 ml methanol, centrifuged for 15 min at 3000 g and evaporated until 
dryness. The residue was dissolved in 200 µl methanol and diluted to 2 ml with milli-Q water. Finally, 
a SPE purification is applied using an Oasis HLB cartridge (60 mg, 3 ml) conditioned with 2 ml 
methanol followed by 2 ml of milli-Q water before applying the 2 ml extract to the cartridge. The 
cartridge is washed twice with 2 ml of milli-Q water and eluted with 2 ml methanol. 
2.3.4 Sample preparation for steroid esters (enzymatic de-esterification) 
Enzymatic hydrolysis of the steroid esters was carried out using esterase from porcine liver. Typically, 
100 µl of the final SPE eluent from samples (see “Sample preparation for androgen bioassay”) was 
evaporated to dryness in a glass tube and the residue incubated with 500 µl sodium phosphate buffer 
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 (0.2M; pH 7.4), 100 µl esterase (20 mg/ml in a Tris-HCl buffer of 50 mM, pH 7.4, 1.15% KCl). The 
final volume was made up to 1.0 ml using milli-Q water, the tube closed and incubated at 37°C in a 
water bath for 6 h. After cooling to room temperature 1 ml acetonitrile was added and the mixture 
centrifuged for 15 min at 3000 g. The supernatant was collected, the residue extracted once more with 
2 ml acetonitrile and centrifuged for 10 min at 3000 g. The combined supernatants were evaporated to 
approximately 0.5 ml and diluted with 3 ml methanol, centrifuged for 15 min at 3000 g and evaporated 
until dryness. The residue was dissolved in 200 µl methanol and diluted to 2 ml with milli-Q water. 
Finally, a SPE purification is applied using an Oasis HLB cartridge (60 mg, 3 ml) conditioned with 2 
ml methanol followed by 2 ml of milli-Q water before applying the 2 ml extract to the cartridge. The 
cartridge is washed twice with 2 ml of milli-Q water and eluted with 2 ml methanol. 
2.3.5 Fractionation of extracts 
The fractionation system consisted of two Knauer (Berlin, Germany) model WellChrom K-1001 
pumps, a Knauer high-pressure dynamic mixing chamber and a Separations (H.I.Ambacht, The 
Netherlands) model 920 autosampler. Liquid chromatography was performed using a Waters (Milford, 
MA) 150 x 3.0 mm i.d. Symmetry column packed with 5 µm C18 packing and a mobile phase 
consisting of (A) water/acetonitrile (90:10) and (B) water/acetonitrile (10:90). Gradient elution was 
performed at a flow rate of 0.4 ml/min, starting at 35% B and linearly programmed to 100% B in 20 
min. The column effluent was split toward two Gilson (Villies-le-Bel, France) model FC203B 96-well 
fraction collectors. 
2.3.6 Recombinant yeast androgen assay 
Aliquots of 200 µl of final extracts were pipetted in a conical 96-well plate (Greiner Bio-One, 
Germany) and 50µl of a 4% solution of DMSO in milli-Q water was added. The plate was left 
overnight in a fume cupboard to allow the acetonitrile to evaporate and leave only the DMSO the next 
day. Aliquots of 200 µl yeast suspension were added to each well of the 96-well plate. A standard 
dose-response curve of 17β-testosterone was included in each experiment. Plates were incubated at 
30°C for 24 h in a shaking incubator (125 rpm), and fluorescence was measured (485 nm excitation, 
530 nm emission) using a SynergyTM HT multidetection microplate reader (BioTek Instruments Inc., 
USA). The optical density (OD) of the yeast was measured at 630 nm after 24 h to monitor for any 
cytotoxic effects on the yeast cells. 
2.3.7 Instrumental analysis: Chromatographic conditions 
Separation of the sample was performed on a Waters Acquity UPLC system consisting of a vacuum 
degasser, an autosampler with a cooled sample tray, a column oven and a binary solvent manager with 
high pressure mixing chamber (Waters, Milford, MA, USA). Elution was performed at a stable 
temperature of 35 ºC using a Waters Acquity BEH-C18 column (100 x 2.1 mm i.d., 1.7 µm particle 
size). The eluents consisted of 0.1% formic acid (A) and acetonitrile/0.1% formic acid in water, 9/1 
(v/v) (B). Ultra pure, LC/MS quality water was used to eliminate excessive background signals and 
avoid the formation of sodium or potassium adducts. A step-wise gradient starting at 0% B was 
employed at a flow of 0.4 ml/min. From 1 to 4 min the %B was linearly increased to 40% and during 4 
to 10 min linearly increased to 100% with a final hold for 2 min. The total run-to-run time (including 
equilibration prior to injection of the next sample) was 13 min. The injection volume was 20 µl. 
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 2.3.8 Instrumental analysis: Mass spectrometry conditions 
The effluent of the HRLC system was directly interfaced to a Bruker Daltonics micrOTOF mass 
spectrometer equipped with an orthogonal electrospray ionisation (ESI) source, operated in the 
positive mode using a mass range of 100 to 1000 Da. The trigger time was 33 µs and 10,000 spectra 
were summed up equaling 0.33 s time resolution. The capillary voltage of the ion source was set at 
3500 V and the capillary exit at 100V. The nebulizer gas pressure was 1.5 L/min and drying gas flow 
8 L/min. The drying temperature was set at 200 °C. Instrument calibration was performed externally 
prior to each sequence with a sodium formate/acetate solution, consisting of 3.3 mM sodium 
hydroxide in a mixture of water/isopropanol/formic acid/acetic acid (1:1:1:3, v/v). The theoretical 
exact masses of calibration ions with formula Na(HCO2Na)2-8 and Na(CH3CO2Na)2-8(HCO2Na)2-8 in 
the range of 100 to 1000 Da were used for calibration. Automated post-run internal mass scale 
calibration of individual samples was performed by injecting the calibrant at the beginning and the end 
of each run via a six-port divert valve equipped with a 20 µL loop. The actual calibration was 
performed based on calibrant injection at the beginning of the run while the calibrant at the end of the 
run was for manual verification of calibration stability. The calibrator ions in the post-run internal 
mass scale calibration were the same as in the instrument calibration.  
2.3.9 Data base construction 
PubChem is a database of chemical molecules (PubChem 2009). The system is maintained by the 
National Center for Biotechnology Information (NCBI), a component of the National Library of 
Medicine, which is part of the United States National Institutes of Health (NIH). PubChem contains 
substance descriptions and small molecules with fewer than 1000 atoms and 1000 bonds and can be 
accessed freely through a web user interface. This option is used to set up a large accurate mass 
database from the PubChem database. It should be mentioned that at the same time the construction of 
a similar database was reported by Polettini who used this in combination with capillary 
electrophoresis ESI/TOFMS (Polettini et al. 2008). A different approach was used by Thurman who 
developed an identification scheme for unknown pesticides using TOFMS and searching for the 
empirical formula using the accurate mass and the Merck Index database (Thurman et al. 2005). The 
PubChem data files were downloaded as text files and converted to an Excel format limiting the 
database to a maximum of 65,000 compounds. These text files contain the trivial and IUPAC name of 
the compounds, the molecular formula and some other information including a PubChem 
identification number. Unfortunately, the database does not contain any CAS numbers which would 
have made the identity and exchangeability with other databases much easier.  
At this point the database contains many compounds that are not suitable for MS detection, not of 
interest for our purpose, or in an ionic form that is not relevant for UPLC-TOFMS analyses. In order 
to remove as many as possible of these compounds and to reduce the size of the database, a subset was 
created by applying the following limitations: a, Molecular mass range from 100 to 750: b, Elements 
limited to C, H, O, N, F, Cl, Br, I, P, S: c, Double entries (several identical compounds with different 
trivial names are included) were removed as far as possible. The final database contains approximately 
40,000 compounds. The theoretical exact mass of the protonated compounds was calculated from the 
elemental compositions using exact atomic masses and correcting for the loss of an electron (i.e. 
calculated as [M+H]+). The database was sorted into columns in the order of exact masses, elemental 
compositions, trivial and IUPAC names, and PubChem identification number. The format was 
converted to make the database compatible with the instrument data analyses software Target 
AnalysisTM (Bruker) and Search LCTM (Thermo Analytical). In addition, the Excel table was converted 
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 to a Windows Access format, and a custom database with a user interface was generated in which 
different parameters such as the type of TOF instrument (Waters LCT versus Bruker TOF) being used, 
the mode of ionisation (positive versus negative), the accurate mass and allowed search mass window 
can be entered. In addition, for each compound the database contains a link to the original PubChem 
database on the internet to find additional information. Figure 2 gives a picture of the user interface of 
the Access format database.  
 
 
Figure 2. User interface of the off-line accurate mass database that was constructed in Windows Access format 
for the identification of compounds based on their accurate mass. 
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 3 Results and Discussion 
3.1 Primary detection of unknown, biological active substances 
The detection and identification of growth promoting, androgenic, compounds was taken as the 
subject for this study. The use of growth-promoting compounds in cattle fattening is prohibited in the 
European Union according to EC directive 96/22 (EC 1996). The EC 96/22 does not contain a list of 
specific compounds that are prohibited, but instead states that all substances having thyrostatic, 
estrogenic, androgenic or gestagenic activity are prohibited. In the same way steroids that enhance the 
performance in sports are on the list of prohibited substances of the World Anti-Doping Agency 
(WADA) (WADA 2008). In livestock production as well as in sports a trend has been observed from 
the abuse of synthetic steroids towards natural steroid esters, pro-hormones and designer modifications 
of existing drugs and the recently discovered “designer” modifications are representative of this trend 
(Pearce et al 2006; Catlin et al. 2002; Catlin et al. 2004; Parr et al. 2009). Pro-hormones such as 
dehydroepiandrosterone (DHEA) are steroid precursors that do not show hormonal activity by 
themselves. Injectable anabolic steroids used in sports such as testosterone cypionate and nandrolone 
decanoate are esters of the parent steroid and are called pro-drugs since they are not active in the ester 
form. After administration and uptake the esters and pro-hormones are metabolized into biologically 
active androgens and estrogens as is illustrated in Figure 3 (Labrie et al. 1998; Lukacik et al. 2006). 
Therefore, feed and sport supplements containing such esters and pro-hormones have the potential to 
enhance the levels of natural occurring steroids and can thus be misused.  
 
Chemical detection methods have the drawback of detecting only targeted compounds of interest. 
However, these supplements may contain anything ranging from the steroids themselves to esters, pro-
hormones and possibly products resulting from metabolic conversions. Therefore, as an alternative 
screening for unknown steroids an in vitro reporter gene bioassay is used for bioactivity testing. Such 
bioassays expressing either the human androgen or progesterone receptor have been used to study the 
hormonal properties of synthesized tetrahydrogestrinone (THG), a designer drug (Death et al 2004). 
More recently, simple yeast-based reporter gene bioassays have been developed for trace analyses of 
estrogens as well as androgens (Bovee et al. 2004a, 2004b). Following metabolic activation using an 
S9 liver extract, inactive pro-hormones will also be detected with such a bioassay, as will inactive 
steroid esters following an enzymatic hydrolysis. Finally, considering that most feed supplements and 
herbal mixtures are of vegetable origin conjugated products as glycosides can be detected also. While 
some conjugated products still show some remaining androgenic activity, these conjugates can be 
converted back into bioactive steroids following a simple enzymatic deconjugation. Since the pro-
hormones may theoretically also exist as their glycosides it is also required to perform multiple 
conversions, e.g. an enzymatic deconjugation followed by a metabolic activation, to include such 
products. An example of the (potential) testing scheme to include such compounds is given Table 1.  
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Figure 3. Conversions of hormone esters (17B-testosterone propionate), hormone glycosides (17B-testosterone 
glycoside), pro-hormones (DHEA, 4-androstene-3,17-dione, 5-androstene-3,17-diol) and pro-hormone 
glycosides (5-androstene-3-hydroxy-17-glycoside) to the bioactive 17B-testosterone by enzymatic hydrolysis, 
enzymatic deconjugation, metabolic activation, and combinations thereof. 
Table 1. Bioassay testing scheme for the detection of hormones, pro-hormones, their glycoside conjugates and 
esters. Only the first five are considered relevant. 
Name Sample treatment before bioassay  
androgen direct bioassay 
glycoside androgen deconjugation – bioassay 
ester androgen hydrolysis – bioassay 
pro-androgen S9 activation (S9) – bioassay 
glycoside pro-androgen deconjugation – S9 activation – bioassay 
ester pro-hormone hydrolysis – S9 activation – bioassay 
glycoside ester androgen deconjugation – hydrolysis – bioassay 
glycoside ester pro-androgen deconjugation – hydrolysis - S9 activation – bioassay 
 
The results of the androgen bioassay on the "cold-case" samples are summarized in Table 2. The direct 
androgen bioassay test did not result in a response of the cells, i.e. no direct hormonal activity was 
observed in vitro. Exceptions were the two digestamin samples that both reacted toxic towards the 
cells, even after 10-fold dilution of the sample extract. Digestamin is a herbal mixture containing 
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 ginger root, fennel seed, rosemary, peppermint, marshmallow, vitamins and minerals. Herbal mixtures 
are sometimes added to food and feed as a anti-bacterial preservative to improve the shelf life of those 
products. A consequence of these anti-bacterial properties is that concentrated herbal extracts 
sometimes react toxic towards the cells in a bioassay. The test for pro-androgens, where the sample 
extract is incubated with an S9-mix prior to testing, was negative for all samples while the control 
samples were positive, indicating that no pro-androgens were detected in the samples.  
 
For the detection of androgen esters an enzymatic hydrolysis was applied to the sample extracts prior 
to testing. While the control samples were positive, indicating a good performance of the test, the 
results for the samples were negative or inconclusive as indicated in Tables 2 and 3 by a +/- sign. Such 
a result can be found if samples contain residues of active compounds, or if structurally different 
compounds are present that show a low biological activity. An example of this is a material to which 
an androgen ester is added. Since the androgen ester preparation often contains some free androgen 
residue as a result of incomplete esterification during synthesis, a direct androgen bioassay of the 
sample material may show a low response. An alternative may be that the sample material contains a 
pro-hormone or steroid derivatives like a steroid ether. Depending on the circumstances small 
fractions of these normally biologically inactive compounds may hydrolyze or metabolically activated 
resulting in a low response in the bioassay. The +/- results for the androgen ester bioassay may for 
instance be the result of the presence of a pro-hormone ester or a glycoside ester androgen in the 
sample material. Although an inconclusive is an indication for the presence of an androgen-like 
compound, they are not representative for the compound group tested for, i.e. for that specific group 
they are considered negative and not further investigated. Androgen glycosides were determined 
following enzymatic deconjugation and as for the esters the results were negative for all "cold-case" 
samples. Finally, the test for pro-androgen glycosides, where two consecutive conversions are required 
prior to the androgen bioassay, showed only negative results. The conclusion of these tests is that none 
of the “cold-case” samples contain compounds with androgenic activity or compounds that produce 
androgens following metabolic activation.  
 
A second group of samples that were tested were herbal mixtures and sport supplements. These 
samples were received from sport schools through intermediates. For the sport supplements the sample 
amounts were limited and therefore the test for pro-androgen glycosides was omitted. While the herbal 
mixtures consist of recognizable herbal material in capsules, the sport supplements are a white 
powdery material in colorful capsules. In this sample series the direct androgen bioassay showed a 
positive response with one of the samples, Herb A4. Logically, the bioassay results of this sample for 
the androgen esters and glycosides are therefore also positive. Pro-androgens were not determined in 
this sample. Another positive response was found for the sample Herb A2, in the test for androgen 
esters, e.g. after enzymatic hydrolysis of the sample extract. Apart from this sample the results of most 
other samples for androgen esters were negative or the sample extracts reacted toxic. For the androgen 
glycosides no positive results were found with the exception of sample Herb A4, which of course 
reacts positive because it was already positive in the direct androgen bioassay. From the results in 
Tables 2 and 3 it was decided to further investigate the samples Herb A2 and A4, and the sport 
supplements S1 to S4. Unfortunately, the available amount of the four sport supplements did not allow 
further bioassay testing so that research was limited to chemical analysis of the sample extracts. Of 
course, the bioassay results do not provide the chemical identity of the bioactive substance and this has 
to be elucidated using screening methods aimed at the identification of the unknown androgenic 
compounds in samples Herb A2 and A4. 
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 Table 2. Results of the androgen bioassay of suspected feed and feed supplements, the “cold cases”. See the text 
for explanation of the signs.  
RIKILT-
code 
Sample description Androgens
Pro-
androgens
Androgen 
esters 
Androgen 
glycosides 
Pro-
androgen 
glycodides
200141597 feed - - - - - 
200141598 feed - - +/- - - 
200144635 feed bigbag - - +/- +/- - 
200144690 
supplement for 
hypophysis activity 
- - +/- - - 
200145516 cod-liver oil - - - - - 
200145518 herbal mixture - - - - - 
200146583 herbal mixture - - - - - 
200146585 herbal mixture - - - - - 
200146589 herbal mixture - - +/- - - 
200148736 all mash - - +/- - - 
200166957 feed - - +/- +/- - 
200207042 herbal mixture - - - - - 
200207177 digestamin piglet tox - +/- - - 
200207178 digestamin fattening tox - +/- +/- - 
Table 3. Results of the androgen bioassay of herbal and sports supplements. See the text for explanation of the 
signs. 
Product 
name 
Sample description Androgens
Pro-
androgens
Androgen 
esters 
Androgen 
glycosides 
Pro-
androgen 
glycodides
Herb A1 herbs in brown capsule - - +/- - nb 
Herb A2 herbs in brown capsule - - + - nb 
Herb A3 herbs in orange capsule - - +/- tox nb 
Herb A4 herbs in orange capsule  + nb + + nb 
Suppl. S1 white powder in capsule tox - +/- +/- nb 
Suppl. S2 white powder in capsule +/- - tox +/- nb 
Suppl. S3 white powder in capsule tox tox tox tox nb 
Suppl. S4 white powder in capsule tox nb nb - nb 
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 3.2 Bioassay guided fractionation of positive samples and UPLC-TOFMS 
identification of the unknown, bioactive compounds 
To pinpoint the bioactive unknown compounds in the positive samples of the previous paragraph, 
bioassay-guided fractionation as illustrated in Figure 1 in the introduction was used. The sample 
extracts of Herb A2 and Herb A4 were analyzed using UPLC/TOFMS and fractionated using an 
HPLC system equipped with dual fraction collection system with 96-well micro-titre plates. A part of 
the chromatogram of the extract of Herb A2 is shown in Figure 4. The results of the androgen activity 
in each collected well is shown directly below each chromatogram in the form of a biogram. The 
negative peaks in the chromatogram result from correction for the blank control samples. The biogram 
of Herb A2 in Figure 4 shows a small positive response in well numbers 54 and 63, correlating with 
retention times around 15.4 and 17.7 min. This is in agreement with the original testing for androgenic 
activity where sample Herb A2 gave a positive, but low androgenic response.  
Although the active fractions of sample Herb A2 collected in wells 53, 54, 55 and 63 were also 
analyzed separately using UPLC/TOFMS, the original unfractionated chromatogram was used for 
identification of the active unknown compounds.  This approach was followed because the low 
response in sample A2 and the dilution of the extract as a consequence of the fractionation procedure 
may lead to compound concentrations that can no longer be detected or identified with 
UPLC/TOFMS.     
 
 
Figure 4. Chromatogram (top) and biogram (bottom) of sample Herb A2. The biogram is corrected for the 
response of blank control samples, hence the negative peaks. The detected response in wells 54 and 63 is 
minimal. 
For the identification of unknown compounds in the chromatogram an accurate mass database 
containing approximately 40,000 compounds was used. The construction of this database will be 
discussed later. By visually inspecting all mass spectra around 15.5 min in the chromatogram of Herb 
A2, two ions were found that differ from the background, the first being m/z 407.2564 at 15.40 min, 
the second m/z 280.2677 at 15.45 min. The chromatogram and the mass spectrum at 15.40 min, 
without and with background subtraction, is shown in Figure 5 indicating the peak of the compound 
with m/z 407.2564.Visual inspection of the mass spectra around 17.7 min showed three ions differing 
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 from the background, the first being m/z 399.2852 at 17.55 min, the second m/z 310.3150 at 17.60 
min, and the third m/z 468.4448 at 17.76 min.  
 
 
Figure 5. Part of the chromatogram around the peak at 15.4 min suspected to contain un unknown compound 
with androgenic properties. The lower windows show the mass spectrum and background subtracted  mass 
spectrum at 15.40 min showing ion m/z 407.2564 differing from the background. 
Using the database the compounds generating these ions were tentatively identified as: 
RT (min) m/z (Da) Tentative identification Molecular formula Δ m/z (mDa) 
Δ m/z 
(ppm) 
15.40 407.2564 Testosterone phenylacetate C27H34O3 1.7 4.2 
  Durabolin (nandrolone phenylpropionate) C27H34O3 1.7 4.2 
  Anticatabolin; Superanabolon C27H34O3 1.7 4.2 
15.45 280.2677 Linoleic acid amide C18H33NO 4.2 15 
  Farnesyl acetone (ammonium adduct) C18H30O 4.2 15 
17.55 399.2852 Benzotest (Testodur) C26H38O3 4.1 10 
17.60 310.3150 no suggestion    
17.75 468.4448 no suggestion    
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 It should be stressed that the identifications are no more than tentative identifications, e.g. preliminary 
identifications. The identity can only be confirmed by analyzing a standard of this compound using the 
same equipment and under the same conditions. If this standard shows the same retention time, mass 
spectrum and/or accurate mass and similar isotope ratios, the identity is "standard confirmed". It 
should also be pointed out that the database contains only protonated ions for the positive mode and 
that identifications therefore will always have the form [M+H]+. Generally, electrospray ionisation 
(ESI) results in protonated molecules [M+H]+ molecules in the positive mode and in deprotonated [M-
H]- molecules in the negative mode. However, several adduct ions such as [M+Na]+, [M+K]+, and 
[M+NH4]+ can be formed in addition to [M+H]+. Carboxyl or carbonyl ether and ester groups are 
believed to be responsible for binding the alkali metal ions originating from the matrix while 
ammonium ions result from addition of ammonium acetate or -formate to the LC mobile phase. The 
formation of such adducts depends on many factors as the presence of ions, the type of organic 
molecules, the type of MS instrument, the ionisation and the geometry of the ionisation chamber (Li et 
al. 2002; Mortier et al. 2004).  
   
Ion m/z 280.2677 was tentatively identified as linoleic acid amide, an endogenous fatty acid primary 
amide found in plants together with other fatty acid amides like oleamide. Nowadays, these amides are 
produced on a large scale and are useful as fiber lubricants, detergents, flotation agents, textile 
softeners, antistatic agents, wax additives, and plasticizers but some of them have also specific 
biological functions. While simple amides of fatty acids were shown to possess an angiogenic factor 
(angiogenesis is the process involved in the growth and development of blood vessels as well as in 
wound healing), no mention of androgenic activity was found in the literature (Wakamatsu et al. 
1990). However, taking into account the possible adduct formation due to the use of ammonium 
formate in the LC mobile phase, ion m/z 280.2677 could also be a [C18H30O+NH4]+ adduct. According 
to the database possible identifications for C18H30O are 2,4,6-tri-t-butylphenol or farnesyl acetone. 
2,4,6-Tri-t-butylphenol is a synthetic compound used in the production of antioxidants for rubbers and 
plastics and as an lubricating agent in the transport sector and therefore not likely to be found in herbal 
preparations. Farnesyl acetone is a terpenoic compound used in the manufacturing of fragrance and 
flavor concentrates of all types and produced in plants from acyclic carotenoids. Considering this 
natural origin farnesyl acetone could also be present in these samples. However, for an ammonium 
adduct loss of the neutral molecule NH3 resulting in the protonated [C18H30O+H]+ molecule is a major 
process. Inspection of the mass spectrum shows no clear sign's of neutral NH3 loss, suggesting that the 
tentative identification as linoleic acid amide is most likely.       
 
Ion m/z 407.2564 was identified as testosterone phenylacetate or Durabolin, Anticatabolin and 
Superanabolon. The latter three are all common names for nandrolone phenylpropionate. Nandrolone 
is a modification of testosterone (methyl-group removed from the 19th position) known as 19-
nortestosterone. Nandrolone is sold commercially as its decanoate ester (Deca-Durabolin) and less 
commonly as a phenylpropionate ester (Durabolin). All identifications are esters, having the same 
molecular formula and can not be further distinguished unless the retention times under the conditions 
of the analyses are known. The finding of an androgen ester is supported by the primary test results 
that indicated that no direct acting androgen was present, but a positive response after enzymatic 
hydrolysis was shown indicating the presence of an androgen ester. As mentioned previously the 
identification are only tentative and should be confirmed by the analysis of a standard of the 
compound or the sample should be analyzed using a confirmatory method. In this case the identity was 
confirmed by the analysis of a sample of Herb A2 using RIKILT procedure RSV-A1025, a qualitative 
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 confirmation method for steroid esters. The identity was standard confirmed as nortestosteron 
phenylpropionate and quantified as a concentration of approximately 0.2 mg/kg product. The latter 
information is of some interest because the bioassay test results of the primary test and of the 96-well 
plates from the fractionation showed that this concentration is close to the detection limit of the 
bioassay for androgen esters. For androgens themselves the detection limit may be lower because no 
enzymatic hydrolysis is needed. Although it is believed that the recovery from enzymatic hydrolysis 
and de-conjugation procedures are generally sufficient (e.g. >70%), incidentally low results can not be 
excluded. In addition, the androgenic potency and thus the sensitivity of the bioassay will be different 
for different compounds. Taking these factors into account detection limits of this method will most 
likely be in the range of 0.1 to 1 mg androgen/kg product. 
 
Ion m/z 399.2852 was identified as Benzotest with Testodur and Virex-retard as alternative names. 
These are all trivial names for testosterone hexahydrobenzoate. It is known as a long-acting 
testosterone ester that was already tested in the '50s (Guiard 1956; Feyel-Cabanes et al. 1958) and has 
more recently been used in medical treatments and been administered to mares (Landier et al. 1984; 
Bonnaire et al. 1995). More recent information about the use of this testosterone ester was not found. 
The database did not produce any suggestions for ions m/z 310.3150 and 468.4448. The compounds in 
the database closest to these ion masses show a mass deviation Δ m/z of 50 mDa (100-150 ppm) and 
since these deviations are more than 10 times higher than those for other compounds they are 
considered unlikely. The database is limited in the sense that it only contains existing compounds and 
does not provide theoretical molecular formulas for accurate masses. However, if theoretical 
molecular formulas are calculated for the two ions using a mass deviation window of 10 mDa, four 
possible molecular formulas C20H40NO, C18H38N4, C19H40N3 and C21H42O are found for ion m/z 
310.3150 while more than 20 are found for ion m/z 468.4448. Of these, the  molecular formulas 
C30H61OP, C28H59N3P, C31H61Cl and C32H56N2 fall within a 1 mDa mass deviation window. Although 
further selections can be made using measured isotope ratios, and the number of rings and double 
bonds in the molecule can be calculated from the molecular formula, in this study we restricted the 
identifications to the accurate mass database.   
 
Summarizing, the presence of nortestosteron phenylpropionate in sample A2 was in part responsible 
for the observed bioactivity in extracts of A2 following enzymatic hydrolysis. The peak of this 
hormone-ester was identified at 15.5 min in the A2 extract chromatogram and it's presence was 
standard confirmed by an independent LC/MSMS analysis containing an external standard of this 
compound. Bioassay guided fractionation indicated the presence of a second hormone-ester that was 
tentatively identified as testosterone hexahydrobenzoate, more commonly known as Testodur. 
Information about this compound is rare and dates from the 50's and 80's of the previous century, it's 
identity remains to be confirmed.    
 
The chromatogram and biogram of sample Herb A4 is presented in Figure 6 and shows strong 
responses in well numbers 25 and 26, correlating to a retention time of 7.0 min in the sample 
chromatogram. Following fractionation of the sample extract of Herb A4 the fractions of well 25 and 
26 showed a clear response in the bioassay and therefore these fractions were analyzed using 
UPLC/TOFMS. As a control, a blank extract (complete method but no sample) was also fractionated 
and the wells 25 and 26 of this blank were analyzed with UPLC/TOFMS in the same series. Figure 7 
shows a part of the chromatogram of well 25 of the blank control (upper chromatogram) and of well 
25 of the fractionated sample extract of Herb A4 (second chromatogram). Comparison shows that 
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 there are two peaks in the sample extract that appear not to be present in the blank control. The first of 
these is found at retention time 7.05 min with m/z 303.2320 and the second at retention time 7.10 min 
with m/z 433.1491. 
 
 
Figure 6. Chromatogram (top) and biogram (bottom) of sample Herb A4. The biogram is corrected for the 
response of blank control samples, hence the negative peak's. The detected response in wells 25 and 26 show a 
clear positive results relative to the other wells. 
 
         
Figure 7. Part of the chromatograms of well 25 after fractionation of a blank control and sample extract of Herb 
A4. Two peaks were identified in the sample extract that are not present in the blank control. These peaks are 
found at retention time 7.05 and 7.10 min and there respective mass spectra are shown below the 
chromatograms. 
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 Using the accurate mass database these peaks were identified as: 
 
RT (min) m/z (Da) Tentative identification 
Molecular 
formula 
Δ m/z 
(mDa) 
Δ m/z 
(ppm) 
NSC307483; Spiro(androstan-3,2'-
oxiran)-17-one ... 
C20H30O2 0.15 0.5 
Usic acid; d-Pimaric acid C20H30O2 0.15 0.5 
Abietic acid; Abietate C20H30O2 0.15 0.5 
MMHDA; 4a-Methylene-17-methyl-A-
homo-B,19-dinorandrost-9-ene-3,17-
diol 
C20H30O2 0.15 0.5 
3,4-Secotrachylobanoic acid C20H30O2 0.15 0.5 
Beyer-15-en-18-oic acid C20H30O2 0.15 0.5 
7.05 303.2320 
3-HMAN; 3-Hydroxy-1-
methyleneandrostan-17-one 
C20H30O2 0.15 0.5 
Tetrahydronorethindrone; 19-Norpregn-
20-yne-3,17-diol 
C20H30O2 0.15 0.5 
Trachyloban-19-oic acid; Trachyloban-
18-oic acid, (4beta)- 
C20H30O2 0.15 0.5 
Mibolerone C20H30O2 0.15 0.5 
Stenbolone C20H30O2 0.15 0.5 
4-Methyltestosterone C20H30O2 0.15 0.5 
7-alpha-Methyltestosterone C20H30O2 0.15 0.5 
17.alpha.-Methyltestosterone C20H30O2 0.15 0.5 
Methenolone C20H30O2 0.15 0.5 
Teideadiol C20H30O2 0.15 0.5 
7.05 303.2320 
Oxendolone; Prostetin C20H30O2 0.15 0.5 
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 Molecular Δ m/z Δ m/z 
RT (min) m/z (Da) Tentative identification 
formula (mDa) (ppm) 
RMI-12936 C20H30O2 0.15 0.5 
Icosapent; Timnodonic acid C20H30O2 0.15 0.5 
17-O-Methyl testosterone ether C20H30O2 0.15 0.5 
Nilevar; Solevar C20H30O2 0.15 0.5 
Peretinoin; Acyclic retinoid C20H30O2 0.15 0.5 
14(R)-Hydroxy-retro-vitamin A C20H30O2 0.15 0.5 
Hepaxanthin; Vitamin A epoxide C20H30O2 0.15 0.5 
5-Hete lactone; 5-
Hydroxyeicosatetraenoic acid lactone ...
C20H30O2 0.15 0.5 
3-Hydroxyretinol C20H30O2 0.15 0.5 
5,6-dehydro AA; 5,6-
dehydroarachidonic acid 
C20H30O2 0.15 0.5 
5,7,9,14,17-Icosapentaenoic acid; 
5,7,9,14,17-Eicosapentaenoic acid 
C20H30O2 0.15 0.5 
Asperketal B C20H30O2 0.15 0.5 
5-Etienic acid; 5-Androstene-17beta-
carboxylic acid 
C20H30O2 0.15 0.5 
PD 140248; 1,8-Naphthyridine-3-
carboxylic acid, 7-(3-(1-aminoethyl-1-
pyrrolidinyl))-1-(2,4-difluorophenyl)-6-
fluoro-1,4-dihydro-4-oxo-, 
hydrochloride (10:11) 
C21H19F3N4O3 
 
1.7 3.9 
Fpl 13210; Fpl-13210; 143305-97-9 
 
C22H29BrN2O2 
 
1.7 3.9 
Podophyllic acid; Diaethyl-(2-chlor-1-
(2,4-dichlorphenyl))-vinyl-phosphat 
 
C22H24O9 
 
0.6 1.4 
7.10 433.1499 
3-Hptmf; Hepta-3; Ambap2359 ... 
 
C22H24O9 
 
0.6 1.4 
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 Molecular Δ m/z Δ m/z 
RT (min) m/z (Da) Tentative identification 
formula (mDa) (ppm) 
Rubropilosin; 2-Hydroxy-4-
hydroxymethyl phenyl 6-O-cinnamoyl-
beta-D-allopyranoside 
 
C22H24O9 
 
0.6 1.4 
 
For m/z 303.2320 the database finds 30 possible identities, all having the molecular formula C20H30O2. 
Information about these compounds can be found in the PubChem database on the internet (PubChem 
2009), or from different sources on the internet using a search engine like Google. Since we know that 
the unknown we are looking for is an androgen we can exclude most of the identities in the list with 
the exceptions of the bold printed compound names. Of these Mibolerone, Stenbolone, 4-, 7- and 17-
methyltestosterone, Methenolone and 17-O-methyl testosterone ether, Nilevar, 3-HMAN and RMI-
12936 are known or likely androgens. The first six of these compounds are all methyltestosterones as 
shown in the molecular structure of testosterone in Figure 8. In 17-O-methyl testosterone ether, or 17-
methoxy testosterone, the hydrogen of the hydroxyl group at the 17-position is replaced by a methyl-
group. Since the human body has no enzymes to remove the ether bond, 17-O-methyltestosterone 
ether is about the only testosterone ether showing anabolic activity (Solo et al. 1975). In Nilevar the 
methyl-group at the 10-position is replaced by a hydrogen while an ethyl-group is bound at the 17-
position together with the hydroxyl-group (Koert et al. 2008). Oxendolone is mentioned in the 
literature as an anti-androgen (Okada et al. 1988). RMI-12936, also known as 7-methyl-17β-hydroxy-
androst-5-en-one was tested for androgenic activity in mouse kidney and was bound by the renal 
androgen receptor with a relative affinity approximately one-third that of testosterone (Bullock et al. 
1978). 3-HMAN (3-hydroxy-1-methyleneandrostan-17-one) was found to be a major urinary 
metabolite of methenolone acetate, an androgen ester, but nothing is mentioned about any androgenic 
acivity (Curehunter 2009). 
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Figure 8. Testosterone structure and numbering, and the structure of four methyl testosterone isomers. 
Compared to testosterone, 4-, 7- and 17-methyl testosterone have an additional methyl group in their respective 
positions. Mibolerone has an additional methyl-group at the 7- and 17-position and a proton instead of a 
methyl-group at the 10 position. Stenbolone has an additional methyl-group at the 2-position and the 4,5-double 
bond has moved to the 1,2-position. Methenolone has an extra methyl-group is at the 1-position and the 4,5-
double-bound has moved to the 1,2-position.  
For m/z 433.1499 the database finds 5 possible identities. PD 140248 is a synthetically produced 
broad-spectrum antimicrobial agent that has been demonstrated to have excellent in vitro activity 
against gram-positive organisms such as staphylococcus and streptococcus infections (Steiert et al. 
2000). The identification as Fpl-13210 (CAS 143305-97-9) with molecular formula C22H29BrN2O2 can 
not be correct since the [M+H]++2 isotope peak with equal intensity as the [M+H]+ peak is missing in 
the mass spectrum. Podophylic acid, or podophyllin is a resinous powder obtained by precipitating an 
alcoholic tincture of the rhizome of American Mayapple (Podophyllum peltatum) by means of water 
acidified with hydrochloric acid. These compounds belong to the podophyllotoxins, a group of 
compounds with potential anti-tumor activity (Tang et al. 2009). 3-Hptmf (CAS 1178-24-1) stands for 
3,3',4',5,6,7,8-Heptamethoxyflavone and no further information was found about this compound. 
Finally, about ruboprilosin no other information was found than that it is related with the production of 
carbohydrates in nature (Perold et al. 1973).  
 
Evaluating the possible identities of both peaks in the chromatogram in Figure 6, it is concluded that 
the peak at 7.05 min in the chromatogram with m/z 303.2320, is most likely responsible for the 
observed androgenic response. This compound with molecular formula C20H30O2, is probably a 
methyltestosterone though it is unknown which exact isomer. The identity was confirmed by the 
analysis of a sample of Herb A4 using a modified version of RIKILT procedure RSV-A1050, an 
analysis method for steroids including 17α-methyltestosterone using derivatization of the hydroxy 
group followed by GC/MSMS analysis. Different from the normal procedure the analysis was 
performed in the scan mode allowing the acquisition of full scan mass spectra which, together with 
retention time information, allow the confirmation of the identity of the compound. The identity was 
standard confirmed as 17α-methyltestosterone quantified at a concentration of approximately 4 mg/kg 
product. The results of the analysis of these herbal mixtures show that the procedure of bioassay 
guided fractionation in combination with UPLC/TOFMS analysis of sample extracts and extract 
fractions, is capable of pin-pointing and identifying the androgenic compounds. It should be added that 
the availability of an adequate accurate mass database is probably a pre-requisite for successful 
compound identification and this database will be the subject for the next paragraph. 
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 3.3 Identifying compounds without primary reference standards 
Apart from the herbal mixtures four sport supplements S1 to S4 were investigated with the bioassay. 
However, the results of the bioassay tests were toxic or inconclusive for most extracts. Since the 
amount of test material was limited it was not possible to investigate these samples further with the 
bioassays. As an alternative approach it was decided to analyze the sample extracts with 
UPLC/TOFMS and use a large database to identify individual compounds in the products as far as 
possible. This accurate mass database was constructed based on compounds extracted from the 
PubChem database that can be found on the internet (PubChem 2009). Interestingly, the database not 
only contains the parent compounds but also many metabolites and conjugated compounds as steroid 
glucuronides, pro-hormones as DHEA and steroid esters as testosterone phenylacetate. For instance, 
using a filter and selecting all compound names containing the term “testosterone” results in 203 
entries, a part of which is shown in the database "report form" shown in Figure 9. The database 
contains 167 entries including the term “glucuronides”, 42 entries containing the term “sulphate” but 
only 2 entries containing the term “glycoside”. It should also be noted that scientific compound names 
are not always used. As an example, compound names as Durabolin, Anticatabolin, Superanabolon 
and nandrolone phenylpropionate, all different names for the same compound, are listed separately in 
the database. However, the commonly used scientific name for this compound, nortestosteron 
phenylpropionate, is not. Another point is that with 40,000 entries in the range of 100 to 750 Da, there 
are many compounds with the same or almost the same mass and as a result more compounds will fall 
into a certain mass tolerance window than when a smaller database would be used. Isotopic pattern 
matching is a powerful criterion in addition to exact mass for compound identification and may be 
able to differentiate between compounds of (nearly) identical mass (Ojanperä et al. 2005), however, if 
the molecular formulas are identical this approach will not help. In the database the average number of 
hits with identical molecular formula is less than 2 with a median value of 1, indicating that in more 
than half of the occasions an accurate mass will produce a molecular formula with only one structural 
isomer. This is visualized by Figure 10 that presents the distribution of the number of isomers in the 
database showing that for 71% of the entries in the database there is only 1 isomer while for 90% of 
the data there are 3 or less isomers. Only for 1% of the entries (still 400 molecular formulas!) the 
number of isomers is in the range of 11 to 32.  
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Figure 9. Screenshot of a part of the database in Excel when a filter for the term “testosterone” was applied. 
Total number of entries found for the term "testosterone" is 203. Exact masses are typically calculated for the 
Bruker MicroTOF but are also available in the database for the Waters LCT.   
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Figure 10. Distribution of the number of isomers in the database showing a range of 1 to 32 isomers with a 
median of 1 isomer and >5 isomers for about 5% of the entries. 
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 The extracts of the sport supplements S1 to S3 (S4 was no longer available) were analyzed using 
UPLC/TOFMS and the accurate mass database was used to identify individual compounds in the 
products as far as possible. At first each chromatogram was searched manually. The search criteria for 
unknown (or untargeted) compounds were ±2 mDa for exact mass deviations, ±20% for the [M+H]++1 
or the [M+H]++2 isotope peak. No retention time information was available. Finally, common sense 
and knowledge about the nature of the sample, in this case the search for androgens in sport 
supplements, was used to decide about the possible identity of a peak in the chromatogram. Figure 11 
shows the chromatogram of sport supplement S1. 
 
 
Figure 11. Chromatogram of an extract of sport supplement S1.  
Although the results for the Herbal samples A2 and A4 in the previous section were obtained by 
manual investigation of the chromatograms, manual investigation without bioassay guided 
fractionation proved extremely laborious. While the use of UPLC/TOFMS generates an enormous 
amount of data allowing the identification of unknown compounds, depending on the matrix, this 
enormous amount of data also causes problems in identification of compounds. Manual searching of 
TOFMS data for unknown compounds of interest is laborious, firstly because peak picking in a typical 
TIC chromatogram of a UPLC/TOFMS analysis is difficult (see Figure 11), secondly because matrix 
interferences and overlapping peaks may seriously hamper the ability to obtain “clean” mass spectra, 
and thirdly because (large) component databases or libraries in UPLC/TOFMS analysis are virtually 
non-existent. For an efficient identification of unknowns elimination of matrix interferences and 
background noise is necessary requiring data reduction routines to “clean-up” the original 
chromatogram. A number of tools for pre-processing of MS data have been proposed in the literature 
(Fiehn et al. 2005; Broeckling et al. 2006; Luedemann et al. 2008) and some are commercially 
available from MS manufacturers such as MetabolynxTM (Waters) that was used previously in this 
study, and SieveTM (ThermoFischer Scientific). MetAlignTM, an interface driven tool for hyphenated 
full-scan mass spectrometry data processing, has been developed in house at RIKILT (Lommen 2009). 
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 While the main purpose of this software is the automated processing of MS-based metabolomics data, 
it is also capable of automatic format conversions, accurate mass calculations, baseline corrections, 
chromatogram alignment, peak-picking, and saturation and mass-peak artifact filtering of data sets, 
resulting in a 100 to 1000 fold data reduction. MetAlignTM is a freeware program that can be 
downloaded from the internet.  
 
In this study MetAlign has been used to reduce the original UPLC/TOFMS data files by baseline 
correction, smoothing and elimination of detector and chemical noise. Figure 12 shows the same 
chromatogram as in Figure 11 but after data pre-processing with MetAlign. Since MetAlign identifies 
unique ion masses and removes noise the number of peaks in the chromatogram seems to increase, 
however, in reality these peaks were already there but obscured by chemical noise. The symmetrical 
peak shapes after pre-processing are inherent to the MetAlign software processing routines. In 
addition, the accurate mass database was placed in an Excel file in a special format that allows it to be 
used by Brukers Target AnalysesTM software to search processed chromatograms for any of these 
compounds. It should be noted that this is a reverse-search process where each ion of interest in the 
database is extracted from the sample file and compared to the accurate mass in the database. This is a 
time-consuming process, but this is how one typically analyzes the data manually. The search criteria 
used to analyse the data files are the accurate mass, the SigmaFitTM and a minimum peak area. The 
SigmaFit is an algorithm developed by Bruker that indicates the exact numerical match between the 
theoretical (calculated from the elemental composition) and measured isotopic patterns. In this way the 
isotopic pattern (or ratio) can be used as an additional identification criterion (Ojanperä et al. 2005). 
Since the pre-processed chromatogram in Figure 12 contains a large number of peaks, each with his 
own accurate mass, this will potentially result in the same large number of molecular formulas. And 
since each molecular formula may result in multiple structural isomers, i.e. different compounds, this 
process may result in a number of identifications in the range of 100-1000. In this case the minimum 
area setting is used to limit the number of “identified” compounds at first. If required the method can 
be made more “sensitive” by lowering the minimum area allowing identifications of smaller peaks in 
the chromatogram. The pre-processed chromatograms of sport supplements S1, S2 and S3 have been 
processed in this way and the identifications reported here are limited to the compounds of interest in 
these samples, e.g. androgens or compounds that were suspected to improve performance in sports. In 
addition, since the database only contains the [M+H]+ ions and no adducts like [M+Na]+, [M+K]+ and 
[M+NH4]+, the latter are also excluded from the search. In the pre-processed chromatogram of sport 
supplement S1 in Figure 12 a number of interesting peaks are marked with capital letters. These 
correspond to the identifications briefly discussed below. Keep in mind that these are no more than 
tentative identifications and confirmation by analysis of the actual standards under the same conditions 
is required to obtain certainty. Compounds of interest identified in the processed chromatograms of 
sport supplements S2 and S3 are found following Figures 13 and 14 respectively.  
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Figure 12. Chromatogram of an extract of sport supplement S1 after pre-processing with MetAlign. 
A: RT = 3.81 min, m/z 329.0865, C14H16O9. Identified as bergenin an isocumeric compound found in 
the Bergenia crassifolia (Siberian Tea), Astilbe thunberg (Ostrich Plume) and Ardisia japonica 
(Marlberry Bush) plants (Ojanperä et al. 2005). Bergenin aids in fat loss and healthy weight 
maintenance by opposing the lipogenic action of insulin and enhancing the lipolytic effects of 
norepinephrine. By preventing fat storage and stimulating fat burning, bergenin is used as a dietary 
weight-loss supplement. 
B: RT = 5.35 min, m/z 289.2160, C19H28O2. While the accurate mass matches with exactly one 
molecular formula, 9 possible identities or names were found. These include testosterone, but also 
epitestosterone, retrosterone, normethandrone, trestolone, dehydroepiandrosterone, benorterone, 3-
hydroxy-4-androsten-17-one, androstane-3, androstanedione and 19-hado.   
C: RT = 5.93 min, m/z 289.2159, C19H28O2. Probably an isomer of peak B. Although the retention 
time and retention time difference between peaks B and C suggest a combination of testosterone 
and epi-testosterone, this is not likely since epitestosterone is the inactive epimer of testosterone 
and thus not likely to be present in an sport supplement.  
D: RT  = 6.34 min, m/z 188.1646, C10H21NO2. Decanohydroxamic acid. 
E: RT = 7.24 min, m/z 272.1279, C16H17NO3. Identified as carbazomycin C or norcoclaurine with the 
latter being a biosynthetic precursor of thebaine and morphine (Loeffler et al. 1987).  
F: RT = 7.77 min, m/z 286.1436, C17H19NO3. Possible identifications are carbazomycin D, coclaurine, 
morphine or norcodeine. 
G: RT = 8.04 min, m/z 301.2159, C20H28O2. For this molecular formula the database reports no less 
than 21 possible isomers including as most notably dianabol, norgesterone and 17-ethylestradiol. 
Dianabol (methylboldenone) is an anabolic steroid released in the US in the early 1960's. It was 
used as an aid to muscle growth by bodybuilders until it was banned by the FDA. 17-ethylestradiol 
has a low anti-estrogenic activity.  
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 H: RT = 9.06 min, m/z 251.2005, C16H26O2. Identified as methyl farnesoate or octoxinol. Octoxinol, 
also known as Triton X-100, is a detergent sometimes used as a antihydroticum, a substance to 
reduce transpiration. However, since octoxinol are usually mixture with multiple ethoxy groups, 
its presence here as a single peak in the chromatogram is unlikely. Methyl farnesoate on the other 
hand is a natural terpenoid compound similar to juvenile hormones in insects and is itself a 
hormone in crustaceans (Laufer et al. 2005).   
I: RT = 9.38 min, m/z 327.1960, C21H26O3. Possibly moxestrol, 2-methoxyethinyl estradiol or 11-
hydroxycannabinol, a metabolite of cannabinol more potent than the parent compound itself. 
J: RT = 10.33 min, m/z 324.2895, C20H37NO2. Peak identified as linoleamide MEA, a common 
compound in household and personal care products. 
 
 
Figure 13. Chromatogram of an extract of sport supplement S2 after pre-processing with MetAlign.  
A: RT = 3.28 min, m/z 181.0722, C7H8N4O2. This peak was identified as theobromine, also known as 
xantheose, a bitter alkaloid of the cacao plant found in chocolate. 
B: RT = 5.52 min, m/z=352.1562, C21H21NO4. Four compounds were reported by the database 
including zindoxifene, an anti-estrogen originally developed as a drug for the treatment of 
hormone-dependent mammary carcinomas (Schneider et al. 1991).  
C: RT = 5.63 min, m/z 703.3059, C32H46N8O6S2. This peak was identified as bisibutiamine, also 
known as sulbutiamine with brand name Arcalion. It is a synthetic derivative of thiamine (vitamin 
B1) and is available for over-the-counter sale as a nutritional supplement. Since this is a lipophilic 
compound a longer retention time is expected and the identification is unlikely. 
D: RT = 9.11 min, m/z 417.2269, C24H32O6. Possible identity is deoxyschisandrin, the composite of 
Schisandra chinensis, a famous Chinese medicine widely used as an anti-stress, anti-aging and 
neurological performance-improving herb (Fu et al. 2008).  
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 E: RT = 9.75 min, m/z 359.2578, C23H34O3. Compounds identified as the androgen esters 7-alpha-
methyltestosterone propionate or testosterone isobutyrate. The longer retention time supports the 
idea that these are the more apolar esters in stead of the free steroids.  
F: RT = 10.07 min, m/z 455,352, C30H46O3. Although the database produced 8 isomers for this 
molecular formula, the most interesting was testosterone buciclate, a relatively new testosterone 
ester which has been synthesized and developed through the initiative of the World Health 
Organization (WHO) and the National Institutes of Health (NHI). It was purposely developed in 
the 1990s as a male contraceptive drug. Testosterone buciclate's androgenic potentials have been 
proven during its clinical testing as it showed more favourable pharmacokinetic characteristics 
than existing compounds, primarily because it is a slow release compound. 
 
 
Figure 14. Chromatogram of an extract of sport supplement S3 after pre-processing with MetAlign.  
A: RT = 7.23 min m/z 272.1284, C16H17NO3. This peak was identified as norcoclaurine, carbazomycin 
C or normorphine (or demethylmorphine). See remarks peak E in Figure 12. 
B: RT = 7.77, m/z 286.1433, C17H19NO3. Coclaurine, carbazomycin D, morphine, norcodeine. 
C: RT = 8.03 min, m/z 301.2155, C20H28O2. Peak identified as methylboldenol (Dianabol). See 
remarks for peak G in Figure 12. 
D: RT = 8.86 min, m/z 268.2271, C16H29NO2. Identified as 1-lauroyl-2-pyrrolidinone or epilachnene, 
an alkaloid and natural macrolide. 
E: RT = 9.03, m/z 251.2007, C16H26O2. Methyl farnesoate, see remarks for peak H in Figure 12. 
F: RT = 9.09, m/z 268.2272, C16H29NO2. Identified as 1-lauroyl-2-pyrrolidinone or epilachnene, see 
remarks peak E. 
G: RT = 9.63, m/z 343.2268, C22H30O3. The database produces 13 isomers for this molecular formula 
with the identification as 6-methylenetestosterone acetate as one of the more likely considering the 
retention time as well as the purpose of this product.  
H: RT = 10.28, m/z 496.3398, C24H50NO7P. Palmitoyl lyso-lectithin. 
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 With all the identifications listed above it should be kept in mind that these are merely tentative 
identifications, an indication that a certain compound, in this case androgens and androgen esters,  
may be present in the sample. To confirm the identity of these compounds a further analyses is 
required using standard reference compounds. However, the results show that unknown identification 
without primary reference standards is feasible using UPLC/TOFMS analysis in combination with 
data processing and accurate mass database searching. For the analysis of the sport supplements this 
resulted in the tentative identification of several androgens, including methylboldenone (Dianabol) and 
testosterone, and the esters methyltestosterone propionate or testosterone isobutyrate, testosterone 
buciclate and methylenetestosterone acetate. In addition, a number of norcodeine- or morphine-like 
compounds are possibly present in these samples.  
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 4 Conclusions 
In this study bioassay directed fractionation combined with UPLC/TOFMS identification was tested as 
a method to detect and identify unknown androgenic compounds. Samples tested comprised of a series 
of “cold cases”, feed supplements suspected to contain growth promoting substances and already 
analyzed in the past, however, without detecting any such compounds. A second set of samples 
consisted of herbs and sport supplements of which it was unknown whether they contained any 
compounds with androgenic activity but which were meant to improve performance in sports. The 
results of the androgen bioassay tests on “cold cases” showed that none of the “cold-case” samples 
contained compounds with androgenic activity. Not only the direct androgen bioassay showed no 
response but also the tests for pro-androgens, androgen esters and conjugated androgens and pro-
androgens did not show positive results indicating the presence of compounds that can metabolically 
be converted into androgens. Two of the four herbal mixtures tested positive, one for the presence of 
an androgen, the second for the presence of an androgen ester. While one of the sport supplements 
tested negative, the results for the others where inconclusive, e.g. indicating the presence of androgen-
like compounds, or they reacted toxic in bioassay tests.  
 
Bioassay guided fractionation of the extracts of the positive herbal mixtures resulted in the isolation of 
the chromatographic fractions contain the compounds responsible for the positive bioassay response. 
Analysis of these fractions using UPLC/TOFMS resulted in the tentative identification of testosterone 
phenylacetate (or the isomeric nortestosterone phenylpropionate) and testosterone hexahydrobenzoate 
in one of the samples and a methyltestosterone isomer in another sample. Using a confirmation 
method the identity of the first testosterone ester was confirmed as nortestosteron phenylpropionate 
with an estimated concentration of 0.2 mg/kg product. The identity of testosterone hexahydrobenzoate 
could not be confirmed since no standard was available. Using GC/MS analysis and comparison of full 
scan mass spectra the identity of the methyltestosterone isomer was confirmed as 17α-
methyltestosterone while it's concentration in the herbal mixture was estimated to be 4 mg/kg product.  
 
For compound identification without primary reference standards an accurate mass database 
containing approximately 40,000 compounds was developed based on the PubChem database on the 
internet. Coupling of this database with the TOFMS software and processing of UPLC/TOFMS data 
files allowed for reversed searching of unknowns in the accurate mass database enabling automatic 
identification of peaks in a chromatogram. For the analysis of the sport supplements this resulted in 
the tentative identification of several androgens, including methylboldenone (Dianabol) and 
testosterone, and the esters methyltestosterone propionate or testosterone isobutyrate, testosterone 
buciclate and methylenetestosterone acetate. In addition, a number of norcodeine- or morphine-like 
compounds are possibly present in these samples. The results show that the procedure of bioassay 
guided fractionation in combination with UPLC/TOFMS analysis and a accurate mass database is very 
useful for the detection and identification of unknown androgenic compounds in feed and sport 
supplements. Based on the bioassay response several androgens and especially androgen esters were 
detected and, in the case of the herbal mixtures, could be isolated using bioassay guided fractionation. 
The combination of UPLC/TOFMS analysis with an accurate mass database proved valuable for the 
identification of unknown compounds especially it allows the tentative identification of unknowns 
even without primary reference standards.  
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 5 Recommendations 
During the study a few promising techniques have been used and the combination of these techniques 
enabled the identification of a number of androgens and pro-androgens. However, it was also noticed 
that the bioassay tests, hoped for to produce a simple "yes/no" response, do not always respond that 
straightforward. On a few occasions the sample reacted toxic in the bioassay, which is believed to 
result from the antimicrobial properties of many herbs. Since it is unknown which compounds in 
different herbal mixtures cause the toxic effects, the only way to eliminate this problem is to dilute the 
herbal extracts prior to the bioassay test. In practice it was noted that toxic reactions are correlated 
with the smell of herbal extracts. Extracts having a strong smell more often show toxic effects so this 
could be used as a rough guide to select those extracts that should be diluted. Dilution, however, will 
affect the detection limit of the bioassay. It is therefore recommended to determine whether or not 
extract dilution is effective in avoiding toxic results, which dilution factor should be used, and what 
that means for the detection limit of the bioassay. Though not really a problem, the sometimes low and 
difficult to interpret bioassay results seem to indicate the presence of a pro-androgen, androgen ester 
or other compound that after chemical conversions may result in an androgen. While it is believed that 
enzymatic hydrolysis and deconjugation will convert most androgen esters en glycosides into the 
corresponding androgen, this is less clear for pro-androgens. The addition of an S9-mix was selected 
to convert these into androgens and while this is tested for dehydroepiandrosterone (DHEA), a pro-
testosterone, the conversion may not work for other pro-androgens. It therefore would be advisable to 
test other pro-androgen if these are available. In addition a sample showing such a low response could 
be tested in a more elaborate way than the conversions listed in Table 1 in this study. 
 
The accurate mass database proved to be a valuable tool for the identification of compounds based on 
accurate mass. While a Windows Access stand alone version of the database was prepared from the 
original Windows Excel file, it can only search for [M+H]+ and [M-H]- ions. Adduct ions like 
[M+Na]+, [M+K]+, [M+NH4]+ and [M+HCO2]- are not incorporated but could be added fairly easily 
making the database more comprehensive. In addition the compounds originally to the database should 
perhaps be reconsidered. Compounds containing sodium (Na) were at the time excluded but since this 
also excluded a number of sodium salts of organic acids it should be reconsidered. To improve the 
quality of the identification additional criteria such as isotopic pattern and especially retention time 
indices could be added to the database. Finally but not least, manual identification of unknowns in 
UPLC/TOFMS data is a laborious process because of the enormous amount of data and on-line 
coupling of the database with the instrument software enabling automatic identification of peaks in the 
chromatogram looks very promising. In this study the accurate mass database was coupled to the 
TOFMS software (Brukers Target Analyses) allowing automatic identification but also introducing 
new difficulties. The configuration used in this study is a "reverse search" routine, i.e. the 
chromatogram is searched for all compounds in the database which is very time-consuming. A 
forward search, searching the database for peaks of interest in the chromatogram is much more 
efficient but only possible if the “peaks of interest” can be selected in the chromatogram. In fact, this 
study is an example of such a forward search routine where the selection of the "peaks of interest" was 
guided by the bioassay, but in the more general case of "identification of unknowns" such a bioassay 
guided process is not available and an alternative peak selection process should be developed. 
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 Finally, the results of the combination of UPLC/TOFMS with data processing and an accurate mass 
database as it was used for identifying compounds without primary reference standards, showed very 
promising results for the development of a method for the identification on unknowns and is 
recommended for further development. For the development of a standard operating procedure 
coupling to TOFMS or OrbitrapMS instruments is required including the development of a forward 
search routine. For the latter the development of data analysis software allowing the setting of 
minimum peak heights or areas for peak selection can be an alternative for the bioassay used in this 
study. In that way it is possible to “tune” the sensitivity of the detection method which can be 
beneficial depending on the knowledge of the sample under investigation.  The introduction of 
additional criteria such as isotopic pattern and especially retention time indices should limit the 
number of false positives, in addition to improved data pre-processing routines, for instance by 
analyzing and subtracting a method blank or even a blank sample if this is available. 
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